Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 12/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.33 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510115 | 0.91 | BUB1 (0.42) | BUB1TGFBR1FLT1FLT4KDR | |
| SCHEMBL2201216 | 0.90 | TGFBR1 (0.44) | BUB1TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL12426216 | 0.90 | TGFBR1 (0.44) | BUB1TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL14461817 | 0.88 | NUDT1 (0.44) | BUB1TGFBR1FLT1FLT4KDR | |
| SCHEMBL12510113 | 0.78 | NUDT1 (0.46) | BUB1TGFBR1FLT1FLT4KDR | |
| SCHEMBL12426215 | 0.78 | TGFBR1 (0.51) | TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL2200730 | 0.78 | TGFBR1 (0.51) | TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL2202010 | 0.78 | BUB1 (0.45) | BUB1TGFBR1ACVR1BACVRL1 | |
| SCHEMBL12426213 | 0.77 | TGFBR1 (0.52) | BUB1TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL2200355 | 0.77 | NUDT1 (0.56) | TGFBR1ACVR1BACVRL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | BUB1 836/4885TGFBR1 3900/4885FLT1 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.